News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron (REGN)'s Delivery Isn't Matching The Hype



9/14/2017 6:31:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The problem with sky-high expectations is that you have to meet them. Regeneron Pharmaceuticals Inc. and its partner Sanofi on

Monday released trial data for their drug Dupixent in treating severe asthma that, while likely good enough to net an FDA approval, fell short enough of very high hopes to send Regeneron shares down 5 percent.

Imperfect data on a pipeline darling is bad news for any company.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES